Nabriva Therapeutics PLC
(STU:NTY)
€
1.25
0.02 (1.63%)
Market Cap: 2.76 Mil
Enterprise Value: 1.62 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 39/100 Nabriva Therapeutics PLC at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019 / 11:20PM GMT
Release Date Price:
€600
(+5.26%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Thank you, everybody. We're going to get moving here in the afternoon with our next company presenter. My name's Jason Gerberry. I'm the U.S. pharma analyst at Bank of America. I'm pleased to be introducing Nabriva and CEO, Ted Schroeder. So Ted, thanks for joining us at the conference.
Theodore R. Schroeder
Nabriva Therapeutics plc - CEO & Director
Hey, thanks for having us, Jason. Always appreciate it.
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
So maybe I'm not sure if you want to provide any introductory remarks as it pertains to Nabriva and helping investors think about how Nabriva takes a differentiated approach to the anti-infective space.
Theodore R. Schroeder
Nabriva Therapeutics plc - CEO & Director
Yes, sure. Thanks. So I think what's different about Nabriva is that we have 2 compounds that are in front of the FDA. So
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot